237 related articles for article (PubMed ID: 23021708)
1. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.
Kerns SL; Stock R; Stone N; Buckstein M; Shao Y; Campbell C; Rath L; De Ruysscher D; Lammering G; Hixson R; Cesaretti J; Terk M; Ostrer H; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e21-8. PubMed ID: 23021708
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer.
Kerns SL; Ostrer H; Stock R; Li W; Moore J; Pearlman A; Campbell C; Shao Y; Stone N; Kusnetz L; Rosenstein BS
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1292-300. PubMed ID: 20932654
[TBL] [Abstract][Full Text] [Related]
3. A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer.
Kerns SL; Stone NN; Stock RG; Rath L; Ostrer H; Rosenstein BS
J Urol; 2013 Jul; 190(1):102-8. PubMed ID: 23376709
[TBL] [Abstract][Full Text] [Related]
4. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Donzella JG
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1069-74. PubMed ID: 11072164
[TBL] [Abstract][Full Text] [Related]
5. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer.
Burri RJ; Stock RG; Cesaretti JA; Atencio DP; Peters S; Peters CA; Fan G; Stone NN; Ostrer H; Rosenstein BS
Radiat Res; 2008 Jul; 170(1):49-59. PubMed ID: 18582155
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer.
Kerns SL; Stock RG; Stone NN; Blacksburg SR; Rath L; Vega A; Fachal L; Gómez-Caamaño A; De Ruysscher D; Lammering G; Parliament M; Blackshaw M; Sia M; Cesaretti J; Terk M; Hixson R; Rosenstein BS; Ostrer H
Radiother Oncol; 2013 Jun; 107(3):372-6. PubMed ID: 23719583
[TBL] [Abstract][Full Text] [Related]
7. Pilot genome-wide association search identifies potential loci for risk of erectile dysfunction in type 1 diabetes using the DCCT/EDIC study cohort.
Hotaling JM; Waggott DR; Goldberg J; Jarvik G; Paterson AD; Cleary PA; Lachin J; Sarma A; Wessells H;
J Urol; 2012 Aug; 188(2):514-20. PubMed ID: 22704111
[TBL] [Abstract][Full Text] [Related]
8. Erectile function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
[TBL] [Abstract][Full Text] [Related]
9. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Wang V; Geybels MS; Jordahl KM; Gerke T; Hamid A; Penney KL; Markt SC; Freedman M; Pomerantz M; Lee GM; Rana H; Börnigen D; Rebbeck TR; Huttenhower C; Eeles RA; Stanford JL; Consortium P; Berndt SI; Claessens F; Sørensen KD; Park JY; Vega A; Usmani N; Mucci L; Sweeney CJ
Prostate; 2021 Jul; 81(10):683-693. PubMed ID: 33956343
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleotide polymorphisms studied for associations with urinary toxicity from (125)I prostate brachytherapy implants.
Usmani N; Leong N; Martell K; Lan L; Ghosh S; Pervez N; Pedersen J; Yee D; Murtha A; Amanie J; Sloboda R; Murray D; Parliament M
Brachytherapy; 2014; 13(3):285-91. PubMed ID: 24656733
[TBL] [Abstract][Full Text] [Related]
11. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction.
Merrick GS; Wallner K; Butler WM; Galbreath RW; Lief JH; Benson ML
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):597-604. PubMed ID: 11395225
[TBL] [Abstract][Full Text] [Related]
12. The effect on erectile function of 103palladium implantation for localized prostate cancer.
Ponholzer A; Oismüller R; Somay C; Büchler F; Maier U; Hawliczek R; Rauchenwald M; Madersbacher S
BJU Int; 2005 Apr; 95(6):847-50. PubMed ID: 15794796
[TBL] [Abstract][Full Text] [Related]
13. Long-term potency preservation following brachytherapy for prostate cancer.
Snyder KM; Stock RG; Buckstein M; Stone NN
BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
[TBL] [Abstract][Full Text] [Related]
14. Associations of VEGF Gene Polymorphisms With Erectile Dysfunction and Related Risk Factors.
Lee YC; Huang SP; Tsai CC; Cheng KH; Juan YS; Wu WJ; Bao BY; Huang CN; Wang CJ; Liu CC
J Sex Med; 2017 Apr; 14(4):510-517. PubMed ID: 28364978
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
16. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
[TBL] [Abstract][Full Text] [Related]
18. Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.
Rudolph A; Hein R; Lindström S; Beckmann L; Behrens S; Liu J; Aschard H; Bolla MK; Wang J; Truong T; Cordina-Duverger E; Menegaux F; Brüning T; Harth V; ; Severi G; Baglietto L; Southey M; Chanock SJ; Lissowska J; Figueroa JD; Eriksson M; Humpreys K; Darabi H; Olson JE; Stevens KN; Vachon CM; Knight JA; Glendon G; Mulligan AM; Ashworth A; Orr N; Schoemaker M; Webb PM; ; ; Guénel P; Brauch H; Giles G; García-Closas M; Czene K; Chenevix-Trench G; Couch FJ; Andrulis IL; Swerdlow A; Hunter DJ; Flesch-Janys D; Easton DF; Hall P; Nevanlinna H; Kraft P; Chang-Claude J;
Endocr Relat Cancer; 2013 Dec; 20(6):875-87. PubMed ID: 24080446
[TBL] [Abstract][Full Text] [Related]
19. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer.
Singh A; Zelefsky MJ; Raben A; Lombardi D; Leibel SA
Int J Cancer; 2000 Oct; 90(5):275-80. PubMed ID: 11091351
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer.
Teloken PE; Ohebshalom M; Mohideen N; Mulhall JP
J Urol; 2007 Dec; 178(6):2521-5. PubMed ID: 17937948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
